TACROLIMUS

Information current as at: 1 June 2026

No activity by the pharmaceutical company has been recorded for this medicine for six(6) months. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: aZematop®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: ARROTEX PHARMACEUTICALS PTY LTD
Condition/indication: (therapeutic use): Atopic dermatitis
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: TACROLIMUS

Submission received for:: July 2025 PBAC meeting
Opportunity for consumer comment:: Open 02/04/2025 and close 28/05/2025 (see PBS Website)
PBAC meeting:: Held on 09/07/2025
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:: Has not yet commenced
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a1079

Page last updated

30 April 2026

v.9.19